Bio-Techne Corp (TECH) - Net Assets
Based on the latest financial reports, Bio-Techne Corp (TECH) has net assets worth $2.11 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.59 Billion) and total liabilities ($478.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Bio-Techne Corp to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.11 Billion |
| % of Total Assets | 81.5% |
| Annual Growth Rate | 19.28% |
| 5-Year Change | 23.94% |
| 10-Year Change | 121.72% |
| Growth Volatility | 18.31 |
Bio-Techne Corp - Net Assets Trend (1989–2026)
This chart illustrates how Bio-Techne Corp's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Bio-Techne Corp (TECH) total market value.
Annual Net Assets for Bio-Techne Corp (1989–2026)
The table below shows the annual net assets of Bio-Techne Corp from 1989 to 2026. Also explore Bio-Techne Corp (TECH) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | $2.11 Billion | +9.87% |
| 2025-06-30 | $1.92 Billion | -7.25% |
| 2024-06-30 | $2.07 Billion | +5.20% |
| 2023-06-30 | $1.97 Billion | +15.61% |
| 2022-06-30 | $1.70 Billion | +8.26% |
| 2021-06-30 | $1.57 Billion | +13.76% |
| 2020-06-30 | $1.38 Billion | +18.50% |
| 2019-06-30 | $1.17 Billion | +8.01% |
| 2018-06-30 | $1.08 Billion | +13.50% |
| 2017-06-30 | $950.83 Million | +8.14% |
| 2016-06-30 | $879.28 Million | +3.82% |
| 2015-06-30 | $846.93 Million | +6.50% |
| 2014-06-30 | $795.26 Million | +7.83% |
| 2013-06-30 | $737.54 Million | +9.36% |
| 2012-06-30 | $674.44 Million | +15.07% |
| 2011-06-30 | $586.12 Million | +16.81% |
| 2010-06-30 | $501.79 Million | +9.93% |
| 2009-06-30 | $456.48 Million | -6.29% |
| 2008-06-30 | $487.13 Million | +11.31% |
| 2007-06-30 | $437.65 Million | +28.59% |
| 2006-06-30 | $340.35 Million | +27.06% |
| 2005-06-30 | $267.87 Million | -9.94% |
| 2004-06-30 | $297.43 Million | +25.70% |
| 2003-06-30 | $236.62 Million | +14.58% |
| 2002-06-30 | $206.52 Million | +16.24% |
| 2001-06-30 | $177.66 Million | +25.87% |
| 2000-06-30 | $141.15 Million | +45.81% |
| 1999-06-30 | $96.80 Million | +51.72% |
| 1998-06-30 | $63.80 Million | +32.64% |
| 1997-06-30 | $48.10 Million | +23.65% |
| 1996-06-30 | $38.90 Million | +31.86% |
| 1995-06-30 | $29.50 Million | +28.26% |
| 1994-06-30 | $23.00 Million | +29.21% |
| 1993-06-30 | $17.80 Million | +58.93% |
| 1992-06-30 | $11.20 Million | +77.78% |
| 1991-06-30 | $6.30 Million | +36.96% |
| 1990-06-30 | $4.60 Million | +48.39% |
| 1989-06-30 | $3.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bio-Techne Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 127032.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2026)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.14 Billion | 54.27% |
| Common Stock | $1.56 Million | 0.07% |
| Other Comprehensive Income | $-70.58 Million | -3.35% |
| Other Components | $1.03 Billion | 49.00% |
| Total Equity | $2.11 Billion | 100.00% |
Bio-Techne Corp Competitors by Market Cap
The table below lists competitors of Bio-Techne Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ZTO EXPRESS (CAYMAN)
F:ZTOB
|
$11.34 Billion |
|
Comerica Incorporated
NYSE:CMA
|
$11.35 Billion |
|
American Homes 4 Rent
NYSE:AMH
|
$11.35 Billion |
|
ENKA Insaat ve Sanayi AS
IS:ENKAI
|
$11.35 Billion |
|
Hecla Mining Company
NYSE:HL
|
$11.30 Billion |
|
A.P.MOELL-M.B U.ADR 1/200
F:DP4H
|
$11.30 Billion |
|
Indian Railway Finance Corporation Limited
NSE:IRFC
|
$11.30 Billion |
|
Gaming & Leisure Properties
NASDAQ:GLPI
|
$11.28 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bio-Techne Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 1,918,808,000 to 2,108,221,000, a change of 189,413,000 (9.9%).
- Net income of 181,862,000 contributed positively to equity growth.
- Dividend payments of 49,916,000 reduced retained earnings.
- Share repurchases of 41,675,000 reduced equity.
- Other comprehensive income decreased equity by 10,700,000.
- Other factors increased equity by 109,842,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $181.86 Million | +8.63% |
| Dividends Paid | $49.92 Million | -2.37% |
| Share Repurchases | $41.67 Million | -1.98% |
| Other Comprehensive Income | $-10.70 Million | -0.51% |
| Other Changes | $109.84 Million | +5.21% |
| Total Change | $- | 9.87% |
Book Value vs Market Value Analysis
This analysis compares Bio-Techne Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.41x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2954.62x to 5.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-06-30 | $0.02 | $72.61 | x |
| 1990-06-30 | $0.03 | $72.61 | x |
| 1991-06-30 | $0.05 | $72.61 | x |
| 1992-06-30 | $0.08 | $72.61 | x |
| 1993-06-30 | $0.12 | $72.61 | x |
| 1994-06-30 | $0.16 | $72.61 | x |
| 1995-06-30 | $0.19 | $72.61 | x |
| 1996-06-30 | $0.25 | $72.61 | x |
| 1997-06-30 | $0.31 | $72.61 | x |
| 1998-06-30 | $0.41 | $72.61 | x |
| 1999-06-30 | $0.58 | $72.61 | x |
| 2000-06-30 | $0.84 | $72.61 | x |
| 2001-06-30 | $1.04 | $72.61 | x |
| 2002-06-30 | $1.21 | $72.61 | x |
| 2003-06-30 | $1.41 | $72.61 | x |
| 2004-06-30 | $1.78 | $72.61 | x |
| 2005-06-30 | $1.64 | $72.61 | x |
| 2006-06-30 | $2.15 | $72.61 | x |
| 2007-06-30 | $2.77 | $72.61 | x |
| 2008-06-30 | $3.10 | $72.61 | x |
| 2009-06-30 | $3.01 | $72.61 | x |
| 2010-06-30 | $3.36 | $72.61 | x |
| 2011-06-30 | $3.94 | $72.61 | x |
| 2012-06-30 | $4.56 | $72.61 | x |
| 2013-06-30 | $5.00 | $72.61 | x |
| 2014-06-30 | $5.37 | $72.61 | x |
| 2015-06-30 | $5.69 | $72.61 | x |
| 2016-06-30 | $5.89 | $72.61 | x |
| 2017-06-30 | $6.34 | $72.61 | x |
| 2018-06-30 | $7.09 | $72.61 | x |
| 2019-06-30 | $7.49 | $72.61 | x |
| 2020-06-30 | $8.76 | $72.61 | x |
| 2021-06-30 | $9.65 | $72.61 | x |
| 2022-06-30 | $10.37 | $72.61 | x |
| 2023-06-30 | $12.15 | $72.61 | x |
| 2024-06-30 | $12.87 | $72.61 | x |
| 2025-06-30 | $12.01 | $72.61 | x |
| 2026-06-30 | $13.43 | $72.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bio-Techne Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.63%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.97%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.27x
- Recent ROE (8.63%) is below the historical average (17.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1989 | 12.90% | 3.20% | 2.05x | 1.97x | $90.00K |
| 1990 | 21.74% | 6.37% | 1.96x | 1.74x | $540.00K |
| 1991 | 25.40% | 8.29% | 2.01x | 1.52x | $970.00K |
| 1992 | 17.86% | 8.97% | 1.42x | 1.40x | $880.00K |
| 1993 | 24.72% | 15.33% | 1.41x | 1.15x | $2.62 Million |
| 1994 | 22.17% | 12.66% | 1.50x | 1.17x | $2.80 Million |
| 1995 | 22.71% | 14.05% | 1.40x | 1.16x | $3.75 Million |
| 1996 | 22.11% | 15.75% | 1.23x | 1.14x | $4.71 Million |
| 1997 | 22.66% | 17.90% | 1.13x | 1.12x | $6.09 Million |
| 1998 | 23.82% | 22.59% | 0.92x | 1.14x | $8.82 Million |
| 1999 | 17.25% | 18.37% | 0.73x | 1.28x | $7.02 Million |
| 2000 | 18.83% | 25.60% | 0.58x | 1.28x | $12.47 Million |
| 2001 | 19.16% | 29.51% | 0.54x | 1.21x | $16.28 Million |
| 2002 | 13.14% | 20.73% | 0.55x | 1.15x | $6.48 Million |
| 2003 | 19.19% | 31.31% | 0.55x | 1.11x | $21.73 Million |
| 2004 | 17.80% | 32.82% | 0.50x | 1.09x | $23.19 Million |
| 2005 | 24.69% | 37.02% | 0.61x | 1.10x | $39.35 Million |
| 2006 | 21.55% | 36.20% | 0.55x | 1.09x | $39.32 Million |
| 2007 | 19.45% | 38.08% | 0.49x | 1.04x | $41.35 Million |
| 2008 | 21.26% | 40.23% | 0.51x | 1.04x | $54.84 Million |
| 2009 | 23.06% | 39.87% | 0.56x | 1.03x | $59.59 Million |
| 2010 | 21.88% | 40.80% | 0.52x | 1.03x | $59.60 Million |
| 2011 | 19.16% | 38.73% | 0.47x | 1.05x | $53.69 Million |
| 2012 | 16.66% | 35.71% | 0.44x | 1.07x | $44.89 Million |
| 2013 | 15.26% | 36.24% | 0.40x | 1.05x | $38.81 Million |
| 2014 | 13.95% | 31.01% | 0.41x | 1.08x | $31.42 Million |
| 2015 | 12.72% | 23.82% | 0.43x | 1.26x | $23.04 Million |
| 2016 | 11.88% | 20.94% | 0.44x | 1.28x | $16.55 Million |
| 2017 | 8.13% | 13.73% | 0.36x | 1.64x | $-17.80 Million |
| 2018 | 11.62% | 19.49% | 0.40x | 1.48x | $17.44 Million |
| 2019 | 8.24% | 13.46% | 0.38x | 1.62x | $-20.49 Million |
| 2020 | 16.60% | 31.04% | 0.36x | 1.47x | $91.18 Million |
| 2021 | 8.98% | 15.08% | 0.41x | 1.45x | $-15.89 Million |
| 2022 | 15.99% | 24.61% | 0.48x | 1.35x | $101.87 Million |
| 2023 | 14.51% | 25.10% | 0.43x | 1.34x | $88.61 Million |
| 2024 | 8.13% | 14.50% | 0.43x | 1.31x | $-38.78 Million |
| 2025 | 3.83% | 6.02% | 0.48x | 1.33x | $-118.48 Million |
| 2026 | 8.63% | 14.97% | 0.45x | 1.27x | $-28.96 Million |
Industry Comparison
This section compares Bio-Techne Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,284,061
- Average return on equity (ROE) among peers: -25.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bio-Techne Corp (TECH) | $2.11 Billion | 12.90% | 0.23x | $11.33 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $110.17 Million |
| Abcellera Biologics Inc (ABCL) | $966.90 Million | -15.14% | 0.40x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $9.08 Million | -66.39% | 1.81x | $308.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $960.81 Million |
| ABVC Biopharma Inc (ABVC) | $-124.82K | 0.00% | 0.00x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.95 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.56 Billion |
About Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of l… Read more